Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination

Corporate Breaking News

Home : Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination

Jun 03 2019	Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination
OSLO, Norway, June 3, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a...


Source:https://www.prnewswire.com:443/news-releases/targovax-announces-publication-of-in-vivo-abscopal-effect-of-oncos-102-and-keytruda-combination-300860388.html

Related News
» The Opening of the Emerald Bay Hotel Further Upgrades the Groundbreaking Archeology Themed Cambrian Town Happy World Resort » Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials